| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 51 | 2026 | 920 | 5.930 |
Why?
|
| Electronic Nicotine Delivery Systems | 12 | 2025 | 60 | 5.280 |
Why?
|
| Tobacco Smoke Pollution | 16 | 2020 | 93 | 4.830 |
Why?
|
| Tobacco Use Disorder | 10 | 2025 | 87 | 4.090 |
Why?
|
| Smoking Prevention | 7 | 2018 | 34 | 3.030 |
Why?
|
| Anti-Asthmatic Agents | 9 | 2026 | 133 | 2.940 |
Why?
|
| Vaping | 6 | 2025 | 31 | 2.620 |
Why?
|
| Smoking | 13 | 2024 | 928 | 2.590 |
Why?
|
| Adrenal Cortex Hormones | 12 | 2026 | 331 | 2.510 |
Why?
|
| Tobacco Products | 7 | 2024 | 59 | 2.410 |
Why?
|
| Smoking Cessation | 9 | 2025 | 189 | 2.160 |
Why?
|
| Medicaid | 15 | 2026 | 251 | 1.690 |
Why?
|
| Nicotine | 7 | 2025 | 115 | 1.690 |
Why?
|
| Tobacco Industry | 3 | 2018 | 6 | 1.580 |
Why?
|
| Public Policy | 3 | 2016 | 54 | 1.430 |
Why?
|
| Lung | 4 | 2025 | 1530 | 1.310 |
Why?
|
| Palivizumab | 3 | 2018 | 48 | 1.120 |
Why?
|
| Managed Care Programs | 9 | 2023 | 54 | 1.110 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2026 | 79 | 1.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2015 | 231 | 1.040 |
Why?
|
| Mothers | 3 | 2016 | 376 | 1.030 |
Why?
|
| Emergency Service, Hospital | 9 | 2026 | 1212 | 1.030 |
Why?
|
| Commerce | 2 | 2016 | 58 | 0.950 |
Why?
|
| Adolescent | 52 | 2026 | 20794 | 0.910 |
Why?
|
| Child Health Services | 2 | 2016 | 86 | 0.880 |
Why?
|
| Respiratory Sounds | 2 | 2018 | 78 | 0.870 |
Why?
|
| Muscular Dystrophies | 1 | 2025 | 51 | 0.850 |
Why?
|
| Child | 60 | 2026 | 26166 | 0.850 |
Why?
|
| United States | 39 | 2026 | 11894 | 0.850 |
Why?
|
| Anthropometry | 1 | 2025 | 187 | 0.830 |
Why?
|
| Body Height | 1 | 2025 | 192 | 0.810 |
Why?
|
| Administration, Inhalation | 9 | 2026 | 192 | 0.800 |
Why?
|
| Drug Monitoring | 1 | 2026 | 288 | 0.770 |
Why?
|
| Humans | 93 | 2026 | 130069 | 0.750 |
Why?
|
| Lung Injury | 2 | 2021 | 123 | 0.740 |
Why?
|
| Varenicline | 1 | 2020 | 12 | 0.650 |
Why?
|
| Bupropion | 1 | 2020 | 26 | 0.640 |
Why?
|
| Parents | 5 | 2017 | 1117 | 0.630 |
Why?
|
| Societies, Medical | 4 | 2025 | 791 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 1282 | 0.580 |
Why?
|
| Hospitalization | 10 | 2026 | 1935 | 0.560 |
Why?
|
| Scoliosis | 2 | 2020 | 147 | 0.560 |
Why?
|
| Drug and Narcotic Control | 1 | 2018 | 16 | 0.550 |
Why?
|
| Marketing | 1 | 2017 | 8 | 0.530 |
Why?
|
| Ozone | 2 | 2016 | 18 | 0.520 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2024 | 78 | 0.510 |
Why?
|
| Medical Overuse | 1 | 2017 | 23 | 0.510 |
Why?
|
| Health Policy | 2 | 2018 | 225 | 0.510 |
Why?
|
| Pamphlets | 1 | 2016 | 21 | 0.500 |
Why?
|
| Drug Prescriptions | 2 | 2023 | 230 | 0.490 |
Why?
|
| Bronchodilator Agents | 5 | 2019 | 156 | 0.480 |
Why?
|
| Air Pollutants | 3 | 2016 | 124 | 0.470 |
Why?
|
| Analgesics, Opioid | 5 | 2024 | 484 | 0.470 |
Why?
|
| Male | 49 | 2026 | 64379 | 0.470 |
Why?
|
| Female | 49 | 2026 | 70239 | 0.450 |
Why?
|
| Child, Preschool | 19 | 2026 | 15001 | 0.440 |
Why?
|
| Child Health | 1 | 2015 | 68 | 0.430 |
Why?
|
| Patient Education as Topic | 3 | 2016 | 461 | 0.430 |
Why?
|
| Cohort Effect | 1 | 2014 | 5 | 0.430 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2017 | 241 | 0.410 |
Why?
|
| Respiratory Function Tests | 4 | 2025 | 222 | 0.410 |
Why?
|
| Vital Capacity | 3 | 2025 | 81 | 0.410 |
Why?
|
| Family Relations | 1 | 2014 | 75 | 0.400 |
Why?
|
| Harm Reduction | 3 | 2024 | 12 | 0.390 |
Why?
|
| Respiratory Tract Diseases | 1 | 2013 | 80 | 0.390 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2016 | 395 | 0.360 |
Why?
|
| Cotinine | 2 | 2010 | 25 | 0.360 |
Why?
|
| Fathers | 1 | 2012 | 73 | 0.340 |
Why?
|
| Environmental Exposure | 4 | 2020 | 292 | 0.340 |
Why?
|
| Sex Factors | 2 | 2014 | 1343 | 0.330 |
Why?
|
| Mexican Americans | 4 | 2020 | 162 | 0.330 |
Why?
|
| Cystic Fibrosis | 1 | 2013 | 267 | 0.330 |
Why?
|
| Antiviral Agents | 1 | 2016 | 802 | 0.330 |
Why?
|
| Genome-Wide Association Study | 8 | 2019 | 1827 | 0.320 |
Why?
|
| Infant | 11 | 2023 | 13266 | 0.310 |
Why?
|
| Minority Groups | 4 | 2016 | 259 | 0.300 |
Why?
|
| Albuterol | 4 | 2018 | 53 | 0.290 |
Why?
|
| Young Adult | 19 | 2020 | 9978 | 0.280 |
Why?
|
| Social Class | 4 | 2016 | 213 | 0.270 |
Why?
|
| Retrospective Studies | 10 | 2026 | 17537 | 0.270 |
Why?
|
| Texas | 3 | 2026 | 3655 | 0.260 |
Why?
|
| Genetic Loci | 4 | 2017 | 353 | 0.250 |
Why?
|
| Attitude to Health | 1 | 2008 | 246 | 0.240 |
Why?
|
| Urban Population | 3 | 2016 | 281 | 0.240 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2026 | 60 | 0.240 |
Why?
|
| Prescriptions | 2 | 2024 | 44 | 0.230 |
Why?
|
| Bronchiolitis | 2 | 2017 | 126 | 0.230 |
Why?
|
| Respiratory Tract Infections | 2 | 2020 | 295 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 3407 | 0.220 |
Why?
|
| Ulna | 1 | 2025 | 7 | 0.220 |
Why?
|
| Arm | 1 | 2025 | 71 | 0.210 |
Why?
|
| Administration, Oral | 2 | 2017 | 706 | 0.210 |
Why?
|
| Tibia | 1 | 2025 | 86 | 0.210 |
Why?
|
| Quality of Health Care | 2 | 2004 | 407 | 0.200 |
Why?
|
| Cultural Diversity | 1 | 2004 | 81 | 0.200 |
Why?
|
| Acute Pain | 1 | 2023 | 19 | 0.200 |
Why?
|
| Muscular Dystrophy, Duchenne | 2 | 2020 | 70 | 0.200 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2023 | 774 | 0.190 |
Why?
|
| Abbreviations as Topic | 1 | 2002 | 1 | 0.190 |
Why?
|
| Drug Therapy, Combination | 1 | 2026 | 1165 | 0.190 |
Why?
|
| Adult | 13 | 2021 | 31011 | 0.180 |
Why?
|
| Case-Control Studies | 10 | 2019 | 3349 | 0.170 |
Why?
|
| Phenotype | 2 | 2017 | 4456 | 0.170 |
Why?
|
| Family | 2 | 2017 | 587 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2018 | 2825 | 0.170 |
Why?
|
| Spirometry | 1 | 2021 | 92 | 0.160 |
Why?
|
| Risk Factors | 15 | 2018 | 10959 | 0.160 |
Why?
|
| Dangerous Behavior | 1 | 2020 | 11 | 0.160 |
Why?
|
| Proteins | 2 | 2017 | 1004 | 0.160 |
Why?
|
| Forced Expiratory Volume | 5 | 2019 | 178 | 0.160 |
Why?
|
| Bronchoscopy | 1 | 2021 | 178 | 0.150 |
Why?
|
| Primary Health Care | 2 | 2015 | 770 | 0.150 |
Why?
|
| Patient Compliance | 1 | 2003 | 462 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2023 | 5034 | 0.150 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2020 | 46 | 0.150 |
Why?
|
| Cytidine Deaminase | 1 | 2019 | 31 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2018 | 8547 | 0.150 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2019 | 36 | 0.150 |
Why?
|
| Odds Ratio | 6 | 2016 | 1210 | 0.150 |
Why?
|
| Allergens | 3 | 2016 | 344 | 0.140 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 83 | 0.140 |
Why?
|
| Spinal Fusion | 1 | 2020 | 125 | 0.140 |
Why?
|
| Smad2 Protein | 1 | 2018 | 54 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2018 | 59 | 0.140 |
Why?
|
| Acculturation | 1 | 2019 | 63 | 0.140 |
Why?
|
| Health Communication | 1 | 2018 | 30 | 0.140 |
Why?
|
| Risk | 2 | 2015 | 723 | 0.140 |
Why?
|
| Telomere Homeostasis | 1 | 2018 | 48 | 0.140 |
Why?
|
| Pharmacogenomic Variants | 1 | 2018 | 38 | 0.140 |
Why?
|
| Pregnancy | 4 | 2015 | 7390 | 0.140 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 155 | 0.140 |
Why?
|
| Air Pollution | 2 | 2016 | 78 | 0.140 |
Why?
|
| Flavoring Agents | 1 | 2017 | 2 | 0.130 |
Why?
|
| Peer Influence | 1 | 2017 | 4 | 0.130 |
Why?
|
| Tobacco Smoking | 1 | 2017 | 21 | 0.130 |
Why?
|
| Oxygen | 1 | 2021 | 549 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2021 | 12818 | 0.130 |
Why?
|
| Child Welfare | 1 | 1998 | 70 | 0.130 |
Why?
|
| Genotype | 4 | 2017 | 2588 | 0.130 |
Why?
|
| DNA, Intergenic | 1 | 2017 | 18 | 0.130 |
Why?
|
| Skin Pigmentation | 1 | 2017 | 28 | 0.130 |
Why?
|
| Antiporters | 1 | 2017 | 35 | 0.130 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2017 | 25 | 0.130 |
Why?
|
| Emergency Medical Services | 2 | 2017 | 352 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 91 | 0.130 |
Why?
|
| Telomere | 1 | 2018 | 218 | 0.130 |
Why?
|
| RNA Splicing Factors | 1 | 2017 | 51 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2018 | 173 | 0.120 |
Why?
|
| Public Health | 1 | 2019 | 269 | 0.120 |
Why?
|
| Government Regulation | 1 | 2016 | 44 | 0.120 |
Why?
|
| Particulate Matter | 2 | 2016 | 92 | 0.120 |
Why?
|
| Drug Utilization | 3 | 2004 | 163 | 0.120 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2016 | 49 | 0.120 |
Why?
|
| Gene-Environment Interaction | 2 | 2016 | 127 | 0.120 |
Why?
|
| Cockroaches | 1 | 2016 | 26 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2023 | 5166 | 0.120 |
Why?
|
| Cost Sharing | 1 | 2016 | 1 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2057 | 0.120 |
Why?
|
| Health Personnel | 1 | 2021 | 538 | 0.120 |
Why?
|
| Puerto Rico | 4 | 2019 | 54 | 0.120 |
Why?
|
| Maternal Age | 1 | 2016 | 134 | 0.120 |
Why?
|
| Racism | 1 | 2016 | 51 | 0.120 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 179 | 0.120 |
Why?
|
| Lung Diseases | 2 | 2018 | 397 | 0.110 |
Why?
|
| Stress, Psychological | 2 | 2017 | 532 | 0.110 |
Why?
|
| Algorithms | 1 | 2022 | 1662 | 0.110 |
Why?
|
| Age Factors | 3 | 2017 | 2822 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 509 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2016 | 235 | 0.110 |
Why?
|
| Prevalence | 3 | 2016 | 2687 | 0.110 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 393 | 0.110 |
Why?
|
| Health Expenditures | 1 | 2016 | 134 | 0.100 |
Why?
|
| Patient Readmission | 1 | 1998 | 436 | 0.100 |
Why?
|
| Minority Health | 1 | 2013 | 12 | 0.100 |
Why?
|
| Ikaros Transcription Factor | 1 | 2014 | 34 | 0.100 |
Why?
|
| Immunoglobulin E | 1 | 2014 | 215 | 0.100 |
Why?
|
| Aged | 4 | 2022 | 20821 | 0.100 |
Why?
|
| Urban Health | 1 | 2013 | 83 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 776 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 1931 | 0.100 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2013 | 31 | 0.100 |
Why?
|
| Acute Disease | 1 | 2016 | 1153 | 0.100 |
Why?
|
| Emigration and Immigration | 1 | 2013 | 80 | 0.090 |
Why?
|
| Kallikreins | 1 | 2012 | 26 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 820 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1604 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2012 | 54 | 0.090 |
Why?
|
| Health Behavior | 2 | 2010 | 386 | 0.090 |
Why?
|
| Obesity | 2 | 2015 | 2398 | 0.090 |
Why?
|
| Logistic Models | 5 | 2020 | 1794 | 0.090 |
Why?
|
| Infant, Premature | 1 | 2018 | 861 | 0.090 |
Why?
|
| Gestational Age | 1 | 2016 | 1210 | 0.090 |
Why?
|
| Pediatrics | 2 | 2017 | 1242 | 0.090 |
Why?
|
| Analgesics | 2 | 2024 | 119 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2107 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 222 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2015 | 400 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2018 | 3677 | 0.090 |
Why?
|
| Tracheitis | 1 | 1991 | 14 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2004 | 297 | 0.080 |
Why?
|
| Geriatric Assessment | 1 | 1991 | 183 | 0.080 |
Why?
|
| Cross-Sectional Studies | 5 | 2018 | 3782 | 0.080 |
Why?
|
| Mice | 2 | 2025 | 18157 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6765 | 0.070 |
Why?
|
| Chromosome Mapping | 3 | 2018 | 1045 | 0.070 |
Why?
|
| Intubation, Intratracheal | 1 | 1991 | 212 | 0.070 |
Why?
|
| Social Support | 1 | 1991 | 369 | 0.070 |
Why?
|
| Counseling | 1 | 2010 | 236 | 0.070 |
Why?
|
| Interviews as Topic | 2 | 2017 | 455 | 0.070 |
Why?
|
| Child Day Care Centers | 1 | 2008 | 24 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2013 | 270 | 0.070 |
Why?
|
| Mental Health | 1 | 1991 | 374 | 0.070 |
Why?
|
| State Health Plans | 2 | 2004 | 4 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2004 | 759 | 0.070 |
Why?
|
| Poverty | 3 | 2014 | 461 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 4035 | 0.060 |
Why?
|
| Creatinine | 1 | 2008 | 396 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 1991 | 561 | 0.060 |
Why?
|
| Animals | 2 | 2025 | 33656 | 0.060 |
Why?
|
| Respiratory Therapy | 1 | 2004 | 19 | 0.050 |
Why?
|
| Poisson Distribution | 1 | 2004 | 50 | 0.050 |
Why?
|
| Family Practice | 1 | 2004 | 82 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2004 | 1374 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 903 | 0.050 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2024 | 69 | 0.050 |
Why?
|
| Data Collection | 1 | 2004 | 370 | 0.050 |
Why?
|
| Mental Recall | 1 | 2002 | 136 | 0.040 |
Why?
|
| Caregivers | 1 | 2008 | 589 | 0.040 |
Why?
|
| Linear Models | 1 | 2023 | 685 | 0.040 |
Why?
|
| Pain | 1 | 2024 | 431 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2006 | 502 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2001 | 76 | 0.040 |
Why?
|
| Vaccination | 1 | 2006 | 1052 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2002 | 181 | 0.040 |
Why?
|
| Middle Aged | 1 | 2020 | 28314 | 0.040 |
Why?
|
| Health Status | 1 | 2002 | 371 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2002 | 237 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 145 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2006 | 703 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2016 | 1694 | 0.040 |
Why?
|
| Communication | 1 | 2003 | 540 | 0.030 |
Why?
|
| Disease Progression | 2 | 2016 | 2191 | 0.030 |
Why?
|
| Educational Status | 2 | 2013 | 276 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2004 | 1042 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 183 | 0.030 |
Why?
|
| Louisiana | 1 | 1997 | 137 | 0.030 |
Why?
|
| Sulfur Dioxide | 1 | 2016 | 7 | 0.030 |
Why?
|
| Geography, Medical | 1 | 2016 | 15 | 0.030 |
Why?
|
| Nitrogen Dioxide | 1 | 2016 | 25 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 907 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 41 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 239 | 0.030 |
Why?
|
| Leukotriene Antagonists | 1 | 2015 | 15 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 257 | 0.030 |
Why?
|
| Education, Nonprofessional | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 800 | 0.030 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2014 | 15 | 0.030 |
Why?
|
| Immunization | 1 | 2016 | 269 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 310 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2014 | 94 | 0.030 |
Why?
|
| San Francisco | 1 | 2013 | 19 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 393 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 709 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2016 | 278 | 0.020 |
Why?
|
| Global Health | 1 | 2018 | 622 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2014 | 137 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2004 | 6401 | 0.020 |
Why?
|
| Income | 1 | 2013 | 137 | 0.020 |
Why?
|
| Environmental Monitoring | 1 | 2013 | 99 | 0.020 |
Why?
|
| Skin Tests | 1 | 2013 | 100 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2013 | 142 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 363 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 169 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2012 | 82 | 0.020 |
Why?
|
| Institutionalization | 1 | 1991 | 13 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2018 | 1544 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 1674 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 1991 | 105 | 0.020 |
Why?
|
| Personality Inventory | 1 | 1991 | 178 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 777 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3321 | 0.020 |
Why?
|
| Disease Management | 1 | 2014 | 554 | 0.020 |
Why?
|
| Feedback | 1 | 2010 | 143 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2010 | 253 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 1991 | 460 | 0.020 |
Why?
|
| Genome, Human | 1 | 2014 | 1318 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 2400 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 3026 | 0.010 |
Why?
|
| Breathing Exercises | 1 | 2004 | 8 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2004 | 70 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 6165 | 0.010 |
Why?
|
| Terminal Care | 1 | 2004 | 117 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2003 | 276 | 0.010 |
Why?
|
| Malnutrition | 1 | 2004 | 156 | 0.010 |
Why?
|
| Vulnerable Populations | 1 | 2003 | 149 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 2004 | 199 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 500 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2004 | 499 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 1241 | 0.010 |
Why?
|